Mirae Asset Global Investments Co. Ltd. Boosts Holdings in Danaher Co. (NYSE:DHR)

Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Danaher Co. (NYSE:DHR) by 3.8% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 79,222 shares of the conglomerate’s stock after acquiring an additional 2,879 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Danaher were worth $21,821,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in DHR. Vicus Capital purchased a new position in shares of Danaher in the first quarter worth $209,000. Cornerstone Wealth Group LLC purchased a new position in shares of Danaher in the first quarter worth $261,000. Breakwater Capital Group increased its stake in shares of Danaher by 5.6% in the first quarter. Breakwater Capital Group now owns 2,353 shares of the conglomerate’s stock worth $588,000 after buying an additional 124 shares during the period. Roberts Wealth Advisors LLC purchased a new position in shares of Danaher in the first quarter worth $256,000. Finally, LVW Advisors LLC purchased a new position in shares of Danaher in the first quarter worth $235,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Danaher news, Director Linda Filler sold 3,928 shares of the business’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $279.50, for a total value of $1,097,876.00. Following the completion of the transaction, the director now owns 41,149 shares of the company’s stock, valued at approximately $11,501,145.50. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 30,059 shares of company stock valued at $8,400,897. 11.10% of the stock is owned by insiders.

Danaher Price Performance

DHR opened at $245.39 on Friday. The stock has a 50-day moving average price of $269.52 and a 200-day moving average price of $260.42. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. The firm has a market cap of $181.76 billion, a PE ratio of 41.59, a P/E/G ratio of 4.49 and a beta of 0.83. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $281.70.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.57 by $0.14. The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. Danaher’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.02 EPS. Sell-side analysts predict that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. The ex-dividend date of this dividend was Friday, September 27th. Danaher’s dividend payout ratio (DPR) is 18.31%.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on DHR. Leerink Partners lifted their target price on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Bank of America lifted their price target on shares of Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Royal Bank of Canada cut their price target on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a report on Wednesday. Raymond James cut their price target on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating on the stock in a report on Wednesday. Finally, KeyCorp lifted their price target on shares of Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a report on Wednesday. Seven investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $287.28.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.